White coat hypertension and masked hypertension
Authors:
Filipovský Jan
Authors place of work:
II. interní klinika Lékařské fakulty v Plzni, Univerzita Karlova, Fakultní nemocnice Plzeň
Published in the journal:
Geriatrie a Gerontologie 2024, 13, č. 2: 92-96
Category:
Review Article
Summary
White-coat hypertension (WCH) is a common phenomenon. It is present in about one third of subjects with office hypertension, typically in females, at higher age and non-smokers. Prognostic data are not enough reliable but some studies with long-term follow-up show that cardiovascular (CV) risk is increased when compared with normotensive subjects. The inverse phenomenon is masked hypertension (MH). Its prevalence in population-based studies is 13 %. It is more common in males, typically aged between 30 and 50 years, smokers with unfavourable risk profile, and in diabetics. The risk of future CV events is close to sustained hypertension. It is underdiagnosed at present, and therefore, home BP measurement should be recommended also to the subjects with normal office BP. There are no prospective trials testing treatment of either WCH or MH. Nonpharmacologic treatment is recommended to the subjects with low CV risk while in high-risk patients, drug treatment should be considered. This is, however, a purely empirical approach.
Keywords:
white coat hypertension, prevalence, diagnosis, treatment, uncontrolled white coat hyper-tension, masked hypertension, prevalence, diagnosis, treatment masked uncontrolled hy-pertension
Zdroje
1. Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA 1988; 259: 225–228.
2. Staessen JA, O’ Brien ET, Amery AK, et al. Ambulatory blood pressure in normotensive and hypertensive subjects: results from an international database. J Hypertens Suppl 1994; 12: S1–12.
3. Conen D, Aeschbacher S, Thijs L, Filipovský J, et al. Age-specific differences between conventional and ambulatory daytime blood pressure values. Hypertension 2014; 64(5): 1073–1079.
4. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013; 62: 168–74.
5. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54: 226–232.
6. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertension 2009; 27: 1672–1678.
7. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005; 45: 203–208.
8. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens 2017; 35: 677–688.
9. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000; 102: 1139–1144.
10. Mancia G, Facchetti F, Parati G, Zanchetti A. Effect of long-term antihypertensive treatment on white-coat hypertension. Hypertension 2014; 64: 1388–1398.
11. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension 2002; 40: 795–796.
12. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertension 2007; 25: 2193–2198.
13. Franklin SS, Thijs L, Li Y, et al.; International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) investigators. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013; 61: 964–71.
Štítky
Geriatrics General practitioner for adults Orthopaedic prostheticsČlánok vyšiel v časopise
Geriatrics and Gerontology
2024 Číslo 2
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Frailty – relationship to selected comorbidities in hospitalized seniors over 28 years
- Diabetic foot syndrome – a serious complication of diabetes mellitus even in the elderly
- Benefits and risks of new antidiabetic drugs for the treatment of elderly diabetics
- New parameters for assessing glucose metabolism in elderly patients with diabetes mellitus